Covid-19: Germany suspends AstraZeneca vaccine amid clotting concerns

Several other European countries have temporarily halted use of the AstraZeneca vaccine in recent days to investigate cases of blood clots that occurred after vaccination

AstraZeneca
Photo: Reuters
APPTI Berlin
2 min read Last Updated : Mar 15 2021 | 8:42 PM IST

The German government said Monday that it's suspending the use of AstraZeneca's coronavirus vaccine over new reports of dangerous blood clots in connection with the shot.

The Health Ministry said the decision was taken as a precaution and on the advice of Germany's national vaccine regulator, the Paul Ehrlich Institute, which called for further investigation of the cases.

In a statement, the ministry said the European Medicines Agency would decide whether and how the new information will affect the authorization of the vaccine.

In its statement, the health ministry said the reported blood clots involved cerebral veins, but didn't specify where or when the incidents occurred. Several other European countries have temporarily halted use of the AstraZeneca vaccine in recent days to investigate cases of blood clots that occurred after vaccination.

AstraZeneca has said there is no cause for concern with its vaccine and that there were fewer reported thrombosis cases in those who received the shot than in the general population.

The European Medicines Agency and the World Health Organization have also said that available data do not suggest the vaccine caused the clots and that people should continue to be immunized.

According to the European Center for Disease Prevention and Control, Germany has received slightly over 3 million doses of the AstraZeneca vaccine and only used 1.35 million doses so far.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :AstraZenecaGermany

First Published: Mar 15 2021 | 8:40 PM IST

Next Story